Orchestra BioMed Holdings, Inc. - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
OBIO Nasdaq 3841 www.orchestrabiomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orchestra BioMed Holdings, Inc.

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy - Oct 1st, 2026 6:00 am
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength? - Sep 21st, 2026 5:33 am
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 - Sep 16th, 2026 6:30 am
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - Sep 15th, 2026 6:30 am
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Aug 27th, 2026 6:30 am
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference - Aug 20th, 2026 6:30 am
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates - Aug 10th, 2026 3:55 pm
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Aug 10th, 2026 2:12 pm
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes - Jun 29th, 2026 6:00 am
Sidoti Events, LLC's June Small-Cap Virtual Conference - Jun 16th, 2026 8:00 am
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2026 2:05 pm
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - May 21st, 2026 5:10 am
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 3:40 pm
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - May 12th, 2026 2:18 pm
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 - May 12th, 2026 6:30 am
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 5:05 pm
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement - May 6th, 2026 6:01 am
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - May 6th, 2026 6:00 am